-
1مورد إلكتروني
مصطلحات الفهرس: phase 1 clinical trial, progression free survival, response evaluation criteria in solid tumors, side effect, speech, travel, writing, aminotransferase, endogenous compound, platinum, programmed death 1 ligand 1, sitravatinib, tislelizumab, gene frequency, advanced cancer, adverse drug reaction, aged, antineoplastic activity, cancer patient, cancer recurrence, cancer survival, case report, clinical article, cohort analysis, conference abstract, disease control, drug combination, drug efficacy, drug safety, drug therapy, drug withdrawal, expert witness, fatigue, female, funding, human, hypertension, multicenter study, ovary carcinoma, parttime employment, pharmacokinetics, Conference Abstract
URL:
https://repository.monashhealth.org/monashhealthjspui/handle/1/36443
Click here for full text options
LibKey Link -
2مورد إلكتروني
مصطلحات الفهرس: female, gene frequency, human, hypertension, multicenter study, ovary carcinoma, pharmacokinetics, phase 1 clinical trial, progression free survival, fatigue, side effect, aminotransferase, endogenous compound, antineoplastic activity, platinum, adverse drug reaction, advanced cancer, response evaluation criteria in solid tumors, clinical article, cohort analysis, conference abstract, disease control, drug combination, drug efficacy, drug safety, drug therapy, drug withdrawal, aged, programmed death 1 ligand 1, sitravatinib, tislelizumab, cancer patient, cancer recurrence, cancer survival, case report, Conference Abstract
URL: Click here for full text options
LibKey Link -
3مورد إلكتروني
مصطلحات الفهرس: phase 1 clinical trial, progression free survival, response evaluation criteria in solid tumors, side effect, speech, travel, writing, aminotransferase, endogenous compound, platinum, programmed death 1 ligand 1, sitravatinib, tislelizumab, gene frequency, advanced cancer, adverse drug reaction, aged, antineoplastic activity, cancer patient, cancer recurrence, cancer survival, case report, clinical article, cohort analysis, conference abstract, disease control, drug combination, drug efficacy, drug safety, drug therapy, drug withdrawal, expert witness, fatigue, female, funding, human, hypertension, multicenter study, ovary carcinoma, parttime employment, pharmacokinetics, Conference Abstract
-
4مورد إلكتروني
مصطلحات الفهرس: female, gene frequency, human, hypertension, multicenter study, ovary carcinoma, pharmacokinetics, phase 1 clinical trial, progression free survival, fatigue, side effect, aminotransferase, endogenous compound, antineoplastic activity, platinum, adverse drug reaction, advanced cancer, response evaluation criteria in solid tumors, clinical article, cohort analysis, conference abstract, disease control, drug combination, drug efficacy, drug safety, drug therapy, drug withdrawal, aged, programmed death 1 ligand 1, sitravatinib, tislelizumab, cancer patient, cancer recurrence, cancer survival, case report, Conference Abstract
-
5مورد إلكتروني
مصطلحات الفهرس: Australia, cancer patient, cancer recurrence, cancer resistance, cancer survival, China, cohort analysis, controlled study, death, disease control, drug combination, drug efficacy, drug safety, drug therapy, drug withdrawal, female, histopathology, human, human cell, human tissue, kidney metastasis, major clinical study, multicenter study, non small cell lung cancer, oncology, ovary carcinoma, pharmacokinetic parameters, pharmacokinetics, phase 1 clinical trial, plasma, progression free survival, response evaluation criteria in solid tumors, tumor microenvironment, endogenous compound, platinum, programmed death 1 ligand 1, programmed death 1 receptor, adult, tislelizumab, conference abstract, advanced cancer, sitravatinib, adverse event, antineoplastic activity, Conference Abstract
URL:
https://repository.monashhealth.org/monashhealthjspui/handle/1/36603
Click here for full text options
LibKey Link -
6مورد إلكتروني
مصطلحات الفهرس: Australia, cancer patient, cancer recurrence, cancer resistance, cancer survival, China, cohort analysis, controlled study, death, disease control, drug combination, drug efficacy, drug safety, drug therapy, drug withdrawal, female, histopathology, human, human cell, human tissue, kidney metastasis, major clinical study, multicenter study, non small cell lung cancer, oncology, ovary carcinoma, pharmacokinetic parameters, pharmacokinetics, phase 1 clinical trial, plasma, progression free survival, response evaluation criteria in solid tumors, tumor microenvironment, endogenous compound, platinum, programmed death 1 ligand 1, programmed death 1 receptor, adult, tislelizumab, conference abstract, advanced cancer, sitravatinib, adverse event, antineoplastic activity, Conference Abstract